Table 2.

Malaria infection prevalence in children (aged 6 months to 14 years) at 12, 18, and 24 months after intervention

	Intention-to-treat analysis			Per protocol analysis
	Malaria prevalence	aOR (95% CI)*	p value†	Malaria prevalence	aOR (95% CI)*	p value†
Pyrethroid-only group
12 months	350/1123 (31·2%)	1 (ref)	..	203/676 (30·0%)	1 (ref)	..
18 months	642/1227 (52·3%)	1 (ref)	..	330/651 (50·7%)	1 (ref)	..
24 months	549/1199 (45·8%)	1 (ref)	..	250/569 (43·9%)	1 (ref)	..
Pyriproxyfen group
12 months	232/1069 (21·7%)	0·69 (0·48–1·04)	0·0754	120/621 (19·3%)	0·59 (0·37–0·95)	0·0286
18 months	583/1153 (50·6%)	0·98 (0·67–1·44)	0·9184	245/541 (45·3%)	0·81 (0·52–1·27)	0·3628
24 months	472/1258 (37·5%)	0·79 (0·54–1·17)	0·2354	151/441 (34·2%)	0·71 (0·45–1·13)	0·1510
Chlorfenapyr group
12 months	176/1126 (15·6%)	0·47 (0·31–0·71)	0·0003	108/716 (15·1%)	0·45 (0·28–0·72)	0·0009
18 months	509/1246 (40·9%)	0·66 (0·45–0·97)	0·0365	254/656 (38·7%)	0·63 (0·40–0·97)	0·0382
24 months	326/1272 (25·6%)	0·45 (0·30–0·67)	0·0001	131/598 (21·9%)	0·39 (0·25–0·63)	0·0001
Piperonyl butoxide group
12 months	206/1071 (19·2%)	0·65 (0·44–0·99)	0·0421	128/627 (20·4%)	0·77 (0·49–1·22)	0·2697
18 months	502/1160 (43·3%)	0·76 (0·52–1·12)	0·1699	192/469 (40·9%)	0·71 (0·45–1·11)	0·1334
24 months	512/1259 (40·7%)	0·99 (0·67–1·45)	0·9607	139/356 (39·0%)	0·97 (0·60–1·55)	0·8891

Prevalence data are n/N (%). For time-by-study group interaction, p_interaction=0·0738 in intention-to-treat analysis and p_interaction=0·2267 in per protocol analysis. Each intervention group is compared against the pyrethroid-only group for the same timepoint. aOR=adjusted odds ratio.

^*Adjusted for baseline cluster-level variables used in restricted randomisation.

^†p<0·017 was considered statistically significant after Bonferroni correction.